CDK4 and neoplasm: In the PALOMA-3 study with a larger cohort of patients, whole-exome sequencing of paired circulating tumor (ct)DNA samples definitively confirmed CDK4/6 specificity of acquired RB1 mutations, but the mutations were detected in only 5% of patients who progressed on the palbociclib and fulvestrant combination [94].